DocGo Announces Fourth Quarter and Full-Year 2024 Results

Rhea-AI Summary

DocGo (NASDAQ: DCGO) reported its Q4 and full-year 2024 financial results. Full-year revenue reached $616.6 million, slightly down from $624.2 million in 2023. The company's GAAP gross margin improved to 32.1% from 28.7% year-over-year, while net income increased to $13.4 million from $10.0 million.

Q4 2024 saw total revenue of $120.8 million, down from $199.2 million in Q4 2023, primarily due to migrant-related programs wind-down. The quarter resulted in a net loss of $7.6 million compared to $8.0 million net income in Q4 2023. The company surpassed 700,000 patient lives assigned for care gap closure programs.

For 2025 guidance, DocGo maintains revenue expectations of $410-450 million but revised adjusted EBITDA margin to approximately 5%, down from previous 8-10% estimate, due to increased investments in care gap closure programs and operational transition.

Positive

• Net income increased to $13.4M in 2024 from $10.0M in 2023
• GAAP gross margin improved to 32.1% from 28.7% YoY
• Patient lives assigned grew to 700,000 from 2,000 YoY
• Strong NPS score of 86 for care gap closure programs
• $150M in migrant-related receivables expected to be collected by Q2 2025

Negative

• Q4 2024 net loss of $7.6M vs $8.0M profit in Q4 2023
• Full-year revenue declined to $616.6M from $624.2M YoY
• Q4 revenue dropped to $120.8M from $199.2M YoY
• 2025 adjusted EBITDA margin guidance lowered to 5% from 8-10%
• Mobile Health Services revenue decreased to $423.1M from $442.8M YoY

Insights

Financial Analyst

DocGo's Q4 and full-year 2024 results reveal a company in strategic transition, with mixed financial performance reflecting both growing pains and promising opportunities. While full-year metrics showed modest improvement—with $616.6 million revenue (slightly down 1.2% year-over-year), $13.4 million net income (up 34%), and improved gross margins at 32.1% (up from 28.7%)—the fourth quarter exposed significant challenges.

The 39% Q4 revenue decline to $120.8 million and swing to a $7.6 million loss highlight the company's vulnerability during its transition away from migrant-related programs. This transition was more abrupt than anticipated, with New York City accelerating wind-downs and creating a $9 million revenue shortfall. The $10 million adjusted EBITDA miss versus guidance raises questions about management's visibility into near-term business dynamics.

Most concerning is the substantial downward revision of 2025 adjusted EBITDA margin guidance from 8-10% to approximately 5%, indicating the transition to core mobile health services requires more investment than initially projected. This suggests either higher-than-expected costs to pivot the business or potentially lower margins in their growing service lines.

The bright spot is DocGo's explosive growth in care gap closure programs, expanding from 2,000 to over 700,000 assigned patient lives in just over a year. The exceptional NPS score of 86 demonstrates strong customer satisfaction in this segment. However, investors should note that scaling these programs requires significant upfront investment before reaching profitable scale.

The $150 million in outstanding migrant-related receivables—representing nearly 25% of annual revenue—warrants monitoring, though management expects collection by Q2 end. This collection timeline will be important for funding the company's transition investments without depleting its $107.3 million cash position.

Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts

Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time

NEW YORK--(BUSINESS WIRE)-- DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced financial and operating results for the quarter and full-year ended December 31, 2024.

Full-Year 2024 Financial Highlights

• Full-year 2024 revenue was $616.6 million, compared to $624.2 million for the full-year 2023.
• GAAP gross margin (which includes non-cash depreciation expenses) for the full-year 2024 was 32.1%, compared to 28.7% for the full-year 2023.
• Adjusted gross margin¹ for the full-year 2024 was 34.6%, compared to 31.3% for the full-year 2023.
• Full-year net income for 2024 was $13.4 million, compared to 2023 full year net income of $10.0 million.
• Full-year 2024 adjusted EBITDA¹ was $60.3 million, compared to $54.0 million for the full-year 2023.
• Full-year 2024 Mobile Health Services revenue was $423.1 million, compared to $442.8 million for the full-year 2023.
• Full-year 2024 Transportation Services revenue was $193.5 million, compared to $181.5 million for the full-year 2023.

Fourth Quarter 2024 Financial Highlights

• Total revenue for the fourth quarter of 2024 was $120.8 million, compared to $199.2 million in the fourth quarter of 2023. The decline was due primarily to the wind-down of migrant-related programs.
• GAAP gross margin (which includes non-cash depreciation expenses) for the fourth quarter of 2024 was 30.8%, compared to 31.2% in the fourth quarter of 2023.
• Adjusted gross margin¹ for the fourth quarter of 2024 was 33.5%, compared to 33.5% in the fourth quarter of 2023.
• Net loss for the fourth quarter of 2024 was $7.6 million, compared to net income of $8.0 million in the fourth quarter of 2023.
• Adjusted EBITDA¹ was $1.1 million for the fourth quarter of 2024, compared to $22.6 million for the fourth quarter of 2023.
• Mobile Health Services revenue for the fourth quarter of 2024 was $71.8 million, compared to $150.4 million for the fourth quarter of 2023. The decline was due primarily to the wind-down of migrant-related programs.
• Transportation Services revenue in the fourth quarter of 2024 was $49.1 million, compared to $48.8 million for the fourth quarter of 2023.
• As of December 31, 2024, the Company held total cash and cash equivalents, including restricted cash, of approximately $107.3 million, compared to $108.5 million as of September 30, 2024.

Results Compared to the Company’s Most Recent Guidance

• Subsequent to the Company’s November 7^th earnings call, the Company was informed by New York City Health and Hospitals (“NYC HH”) that they were now planning to accelerate the wind down of their migrant program, affecting both the scope and scale of those projects. In addition, subsequently, the HPD migrant sites in Upstate NY closed weeks earlier than had been anticipated. These two factors resulted in a negative impact of approximately $9.0 million on Q4 revenue and $5.3 million on Q4 adjusted EBITDA¹.
• The Company witnessed a significant increase in activity in its payer vertical. In anticipation of an expansion of these services, the Company increased levels of investment late in the fourth quarter in several areas, including personnel and related expenses. This increased investment reduced fourth quarter adjusted EBITDA¹ by approximately $1.5 million.
• At year-end, the Company increased loss reserves for both ongoing and as-yet-reported claims across several of its self-insured lines, including auto, worker’s compensation and health. The aggregate increase in costs reduced fourth quarter adjusted EBITDA¹ by approximately $3.2 million.
• Based upon the above unanticipated items, actual adjusted EBITDA¹ in Q4 of 2024 was approximately $10 million lower than the Company’s implied guidance range from early November.

2025 Guidance

• Full-year 2025 revenue is expected to be $410-$450 million, unchanged from the previous estimate.
• Full-year 2025 adjusted EBITDA margin² is now expected to be approximately 5%, down from the previous estimate of 8%-10%. The revision is largely due to increased investment to support the growth of the Company’s care gap closure programs, add expanded mobile health offerings, and transitioning operations from migrant revenue to core mobile health revenue.

Select Corporate Highlights for the Fourth Quarter of 2024 and Recent Weeks

• Surpassed 700,000 patients assigned by its insurance partners for care gap closure programs.
• Signed a two-year contract with a major hospital system in Fort Worth, TX to provide medical transportation services.
• Signed a contract in Mississippi with a major hospital system to provide adult and pediatric remote cardiac monitoring services for approximately 3,000 patients.
• Signed a two-year transportation contract renewal with a major Tennessee healthcare system and announced expansion of services to the Chattanooga region.
• Acquired PTI Health to expand the Company’s portfolio of clinical offerings with mobile phlebotomy services.
• Signed deals with two Veterans Affairs (VA) contractors for the Company to facilitate medical screenings and additional services for Veterans.
• Brought on Dr. David Shulkin – former Secretary of the VA – to help guide the Company’s efforts and drive growth in the population health vertical.
• Made significant investments in the Company’s tech stack to streamline patient intake and reduce booking friction, resulting in a 9% reduction in average booking time compared to the previous quarter.

Lee Bienstock, Chief Executive Officer of DocGo, commented, “We continue to experience strong demand for our care gap closure programs in our payer and provider vertical, and are investing heavily to support this growth. We are expanding our training initiatives, broadening our scope of services and continuing to aggressively build out our footprint while maintaining the highest level of quality. Our number of patient lives assigned has increased to more than 700,000, up from just 2,000 a little over a year ago. Perhaps, most impressively, is that our Net Promoter Score (NPS) in the fourth quarter was 86 for our care gap closure programs. To put that in perspective, in healthcare, above 30 is deemed good, and above 70 is deemed world class. Our patients and customers are delighted with these programs, and we see a substantial opportunity to accelerate our growth in this market via both organic and inorganic means in the coming quarters.” Bienstock continued, “Additionally, we have had a recent flurry of activity in our government population health pipeline which we are confident will translate into second half revenues. This includes both subcontracted, healthcare specific work with major government contractors and new direct opportunities with government entities. We believe the investments we made during the fourth quarter and continue to make will drive our transition from migrant-related revenues to core mobile health revenue.”

Norm Rosenberg, Chief Financial Officer of DocGo, also commented, “While our adjusted EBITDA came in lower than our previous expectations, that was driven in part by higher SG&A to support the growth and buildout of our payer and provider vertical, which included investments in our people, our tech stack and in quality initiatives to ensure we deliver a world-class product. We anticipate that these investments will continue into 2025. We continue to believe that beyond 2025, our business model can achieve double digit adjusted EBITDA margins, as we have demonstrated in the recent past.” Rosenberg added, “We continued to make progress with our cash collections during the fourth quarter and subsequent to year end. As of year-end, we had approximately $150 million in migrant-related project receivables which we expect to largely be collected by the end of the second quarter, supporting further substantial increases in our cash position.”

1. Adjusted gross margin and adjusted EBITDA are non-GAAP financial measures. See “Non-GAAP Financial Measures” below for additional information on these non-GAAP financial measures and reconciliations to the most comparable GAAP measures.
2. Adjusted EBITDA margin is a non-GAAP financial measure. We have not reconciled adjusted EBITDA margin outlook to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management’s control and which could be significant. Because such items cannot be reasonably predicted with the level of precision required, we are unable to provide an outlook for the comparable GAAP measure (net margin). Forward-looking estimates of adjusted EBITDA margin are made in a manner consistent with the relevant definitions and assumptions noted herein.

Conference Call and Webcast Details

Thursday, February 27, 2025 at 5:00 PM ET

1-800-717-1738 - Investors Dial

1-646-307-1865 - Int’l Investors Dial

Conference ID: 41220

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1706503&tp_key=ffa80ce9b1

The webcast can also be accessed under Events on the Investors section of the Company’s website, https://ir.docgo.com/.

About DocGo

DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote advanced practice provider, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.

Forward-Looking Statements

This earnings release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including our expectations around second half revenues and the growth and buildout of our payer and provider vertical; new direct opportunities with government entities; cash collections; the provision of services under its existing contracts, including the winding down of migrant-related services; the expansion of the Company’s programs with insurance partners, hospital systems, municipalities and other strategic partners, including care gap closure programs and government population health programs, and investments related to such programs; and the Company’s cash balances. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking, including, but not limited, to statements regarding the Company’s future actions, business strategies or models, plans, goals, future events, future revenues, future margins, current and future revenue guidance, future growth or performance, financing needs, business trends, results of operations, objectives and intentions with respect to future operations, services and products, and new and existing contracts or partnerships. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions.

Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause the Company’s actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in the Company’s forward-looking statements, including, but not limited to the following: impacts related to the wind down of migrant-related services and associated cash collections; the Company’s ability to expand its programs with insurance partners, hospital systems, municipalities, other government entities and other strategic partners; the Company’s ability to successfully implement its business strategy, including delivering value to shareholders via buybacks, funding new strategic relationships and potentially repaying its line of credit; the Company’s ability to grow demand for its care gap closure programs; the Company’s ability to maintain sufficient cash balances; the Company’s ability to maintain its contractual relationships with its healthcare provider partners and clients; the Company’s ability to compete effectively in a highly competitive industry; the Company’s reliance on government contracts; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s M&A activity; the Company’s ability to retain its workforce and management personnel and successfully manage leadership transitions; the Company’s ability to collect on customer receivables; risks associated with the Company’s share repurchase program; expected impacts of macroeconomic factors, including inflationary pressures, general economic slowdown or a recession, rising interest rates, foreign exchange rate volatility, changes in monetary pressure, financial institution instability or the prospect of a shutdown of the U.S. federal government; potential changes in federal, state or local government policies regarding immigration and asylum seekers; expected impacts of geopolitical instability; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; the Company’s ability to improve gross margins; the Company’s ability to implement and deliver on cost-containment measures and ongoing cost rationalization initiatives; legislative and regulatory actions; the impact of legal proceedings and compliance risk; volatility of the Company’s stock price; the impact on the Company’s business and reputation in the event of information technology system failures, network disruptions, cyber incidents or losses or unauthorized access to, or release of, confidential information; and the ability of the Company to comply with laws and regulations regarding data privacy and protection and other risk factors included in the Company’s filings with the Securities and Exchange Commission (“SEC”).

Moreover, the Company operates in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this earnings release. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results or outcomes could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this earnings release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this earnings release to reflect events or circumstances after the date of this earnings release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law. The Company’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.

DocGo Inc. and Subsidiaries CONSOLIDATED BALANCE SHEETS
	December 31,
	2024			2023
ASSETS
Current assets:
Cash and cash equivalents	$	89,241,695		$	59,286,147
Accounts receivable, net of allowance for credit loss of $5,873,942 and $6,276,454 as of December 31, 2024 and December 31, 2023, respectively		210,899,926			262,083,462
Prepaid expenses and other current assets		4,344,642			17,499,953
Total current assets		304,486,263			338,869,562
Property and equipment, net		14,881,411			16,835,484
Intangibles, net		25,728,813			37,682,928
Goodwill		47,432,550			47,539,929
Restricted cash		18,095,612			12,931,839
Operating lease right-of-use assets		11,958,698			9,580,535
Finance lease right-of-use assets		15,337,299			12,003,919
Investments		5,547,979			553,573
Deferred tax assets		8,422,034			11,888,539
Other assets		3,730,473			2,565,649
Total assets	$	455,621,132		$	490,451,957
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	28,356,430		$	19,827,258
Accrued liabilities		49,896,796			91,340,609
Line of credit		30,000,000			25,000,000
Notes payable, current		12,515			28,131
Due to seller		28,656			7,823,009
Contingent consideration		4,973,152			19,792,982
Operating lease liability, current		3,844,561			2,773,020
Finance lease liability, current		4,694,467			3,534,073
Total current liabilities		121,806,577			170,119,082
Notes payable, non-current		5,215			41,586
Operating lease liability, non-current		8,599,072			7,223,941
Finance lease liability, non-current		10,031,138			7,896,392
Total liabilities		140,442,002			185,281,001
Commitments and contingencies
Stockholders’ equity:
Common stock ($0.0001 par value; 500,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 101,910,883 and 104,055,168 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively)		10,191			10,406
Additional paid-in-capital		321,087,583			320,693,866
Accumulated deficit		(1,402,167	)		(21,394,310	)
Accumulated other comprehensive income		1,221,869			1,484,905
Total stockholders’ equity attributable to DocGo Inc. and Subsidiaries		320,917,476			300,794,867
Noncontrolling interests		(5,738,346	)		4,376,089
Total stockholders’ equity		315,179,130			305,170,956
Total liabilities and stockholders’ equity	$	455,621,132		$	490,451,957

DocGo Inc. and Subsidiaries CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
	Year Ended December 31,
	2024			2023			2022
Revenues, net	$	616,555,132		$	624,288,642		$	440,515,746
Expenses:
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)		402,980,557			428,906,225			285,794,520
Operating expenses:
General and administrative		138,758,758			137,152,512			103,403,416
Depreciation and amortization		15,884,898			16,431,892			10,565,578
Legal and regulatory		17,146,891			13,082,569			8,780,590
Technology and development		11,589,402			10,858,724			5,384,853
Sales, advertising and marketing		1,505,900			2,801,740			4,755,161
Total expenses		587,866,406			609,233,662			418,684,118
Income from operations		28,688,726			15,054,980			21,831,628
Other (expense) income:
Interest (expense) income, net		(1,929,207	)		1,684,399			762,685
Gain on remeasurement of warrant liabilities		-			-			1,127,388
Change in fair value of contingent liability		9,392,133			1,437,525			-
Finite-lived intangible asset impairment		(8,306,591	)		-			-
Goodwill impairment		-			-			(2,921,958	)
(Loss) gain on equity method investments		(316,044	)		(343,336	)		8,919
(Loss) gain on remeasurement of operating and finance leases		(32,363	)		(866	)		1,388,273
Gain on bargain purchase		-			-			1,593,612
Gain (loss) on disposal of fixed assets		23,682			(852,544	)		(21,173	)
Other income (expense)		228,666			(686,865	)		(987,482	)
Total other (expense) income		(939,724	)		1,238,313			950,264
Net income before income tax expense		27,749,002			16,293,293			22,781,892
(Provision for) benefit from income taxes		(14,388,422	)		(6,244,965	)		7,961,321
Net income		13,360,580			10,048,328			30,743,213
Net (loss) income attributable to noncontrolling interests		(6,631,563	)		3,189,873			(3,841,285	)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries		19,992,143			6,858,455			34,584,498
Other comprehensive income
Foreign currency translation adjustment		(263,036	)		743,699			773,707
Total comprehensive income	$	19,729,107		$	7,602,154		$	35,358,205
Net income per share attributable to DocGo Inc. and Subsidiaries - Basic	$	0.20		$	0.07		$	0.34
Weighted-average shares outstanding - Basic		102,395,141			103,511,299			101,228,369
Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted	$	0.18		$	0.06		$	0.34
Weighted-average shares outstanding - Diluted		109,422,840			105,617,817			102,975,831

DocGo Inc. and Subsidiaries CONSOLIDATED STATEMENTS OF CASH FLOWS
	Year Ended December 31,
	2024			2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	13,360,580		$	10,048,328		$	30,743,213
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation of property and equipment		5,606,818			4,829,780			4,114,346
Amortization of intangible assets		5,660,818			5,249,358			3,214,814
Amortization of finance lease right-of-use assets		4,617,262			6,352,754			3,236,418
(Gain) loss on disposal of assets		(23,682	)		852,544			21,173
Deferred income tax		3,466,505			(1,981,519	)		(9,957,967	)
Loss (gain) on equity method investments		316,044			343,336			(8,919	)
Bad debt expense		5,235,560			3,601,520			3,815,187
Stock-based compensation		13,634,086			20,969,174			8,054,571
Loss (gain) on remeasurement of operating and finance leases		32,363			866			(1,388,273	)
Loss on liquidation of business		-			70,284			-
Gain on remeasurement of warrant liabilities		-			-			(1,127,388	)
Gain on bargain purchase		-			-			(1,593,612	)
Finite-lived intangible asset impairment		8,306,591			-			-
Goodwill impairment		-			-			2,921,958
Change in fair value of contingent consideration		(9,392,133	)		(1,437,525	)		-
Changes in operating assets and liabilities:
Accounts receivable		41,272,218			(160,524,934	)		(8,415,793	)
Asset held for sale		-			-			190,312
Prepaid expenses and other current assets		13,007,231			(10,843,890	)		(4,181,035	)
Other assets		(1,384,824	)		1,059,605			1,557,655
Accounts payable		8,562,006			(1,780,403	)		3,637,305
Accrued liabilities		(41,940,373	)		58,968,844			(5,964,064	)
Net cash provided by (used in) operating activities		70,337,070			(64,221,878	)		28,869,901
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment		(3,834,146	)		(7,584,561	)		(3,198,234	)
Acquisition of intangibles		(2,002,103	)		(2,541,661	)		(2,299,558	)
Acquisition of businesses		-			(20,203,464	)		(32,953,179	)
Equity method investments		(310,450	)		(298,932	)		-
Investment in equity securities		(5,000,000	)		-			-
Proceeds from disposal of property and equipment		274,427			747,088			3,000
Net cash used in investing activities		(10,872,272	)		(29,881,530	)		(38,447,971	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving credit line		45,000,000			25,000,000			-
Repayments of revolving credit line		(40,000,000	)		-			(25,881	)
Repayments of notes payable		(51,987	)		(25,926	)		(925,151	)
Due to seller		(3,118,595	)		(13,590,382	)		(2,535,521	)
Acquisition of noncontrolling interest		(1,848,000	)		-			-
Earnout payments on contingent liabilities		(3,608,553	)		(5,266,681	)		-
Dividends paid to noncontrolling interest		(1,294,422	)		-			-
Noncontrolling interest contributions		-			-			2,063,000
Proceeds from exercise of stock options		26,330			1,581,183			1,980,585
Payments for taxes related to shares withheld for employee taxes		(1,168,877	)		(2,308,954	)		-
Common stock repurchased		(13,756,271	)		-			(3,731,712	)
Equity costs		-			-			(19,570	)
Payments on obligations under finance lease		(4,334,463	)		(4,270,553	)		(2,985,568	)
Net cash (used in) provided by financing activities		(24,154,838	)		1,118,687			(6,179,818	)
Effect of exchange rate changes on cash and cash equivalents		(190,639	)		1,093,633			761,232
Net increase (decrease) in cash and restricted cash		35,119,321			(91,891,088	)		(14,996,656	)
Cash and restricted cash at beginning of period		72,217,986			164,109,074			179,105,730
Cash and restricted cash at end of period	$	107,337,307		$	72,217,986		$	164,109,074
	Year Ended December 31,
	2024			2023			2022
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest	$	2,142,288		$	250,100		$	197,005
Cash paid for interest on finance lease liabilities	$	769,041		$	600,239		$	559,596
Cash paid for income taxes	$	7,249,331		$	4,251,658		$	1,505,235
Right-of-use assets obtained in exchange for lease liabilities	$	13,973,620		$	7,621,538		$	5,035,201
Remeasurement of finance lease right-of-use asset due to lease modification	$	300,000		$	-		$	-
Fixed assets acquired in exchange for notes payable	$	-		$	-		$	923,377
Supplemental non-cash investing and financing activities:
Acquisition of remaining FMC NA through due to seller and issuance of stock	$	-		$	7,000,000		$	-
Acquisition of CRMS through issuance of stock	$	-		$	1,000,000		$	-
CRMS True-up Payment through issuance of stock	$	1,814,345		$	-		$	-
Receivable exchanged for trade credits	$	-		$	1,500,000		$	-
Pre-acquisition receivables written off through due to seller	$	4,675,758		$	-		$	-
Reconciliation of cash and restricted cash
Cash	$	89,241,695		$	59,286,147		$	157,335,323
Restricted cash		18,095,612			12,931,839			6,773,751
Total cash and restricted cash shown in statement of cash flows	$	107,337,307		$	72,217,986		$	164,109,074

DocGo Inc. and Subsidiaries CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
	Three Months Ended December 31,
	2024			2023
Revenues, net	$	120,833,073		$	199,246,269
Expenses:
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)		80,334,624			132,559,805
Operating expenses:
General and administrative		35,041,780			43,514,996
Depreciation and amortization		3,322,925			4,615,235
Legal and regulatory		5,524,453			3,493,572
Technology and development		3,685,650			3,185,455
Sales, advertising and marketing		396,828			203,548
Total expenses		128,306,260			187,572,611
(Loss) income from operations		(7,473,187	)		11,673,658
Other income:
Interest (expense) income, net		(541,464	)		6,979
Change in fair value of contingent liability		9,762,845			1,277,551
Finite-lived intangible asset impairment		(8,306,591	)		-
Loss on equity method investments		(86,121	)		(41,974	)
Loss on remeasurement of operating and finance leases		(311	)		(5,700	)
Loss on disposal of fixed assets		(13,035	)		(689,092	)
Other income (expense)		82,608			(25,040	)
Total other income		897,931			522,724
Net (loss) income before income tax expense		(6,575,256	)		12,196,382
Provision for income taxes		(1,071,670	)		(4,203,122	)
Net (loss) income		(7,646,926	)		7,993,260
Net (loss) income attributable to noncontrolling interests		(4,384,116	)		422,789
Net (loss) income attributable to stockholders of DocGo Inc. and Subsidiaries		(3,262,810	)		7,570,471
Other comprehensive income
Foreign currency translation adjustment		(1,091,649	)		676,734
Total comprehensive (loss) income	$	(4,354,459	)	$	8,247,205

DocGo Inc. and Subsidiaries CONSOLIDATED STATEMENTS OF CASH FLOWS
	Three Months Ended December 31,
	2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$	(7,646,926	)	$	7,993,260
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation of property and equipment		1,323,878			132,063
Amortization of intangible assets		776,481			953,400
Amortization of finance lease right-of-use assets		1,222,566			3,529,772
Loss on disposal of assets		13,035			689,092
Deferred income tax		8,709,292			(3,030,755	)
Loss on equity method investments		86,121			41,974
Bad debt expense		1,378,086			3,912,961
Stock-based compensation		3,878,631			5,807,327
Loss on remeasurement of operating and finance leases		311			5,700
Finite-lived intangible asset impairment		8,306,591			-
Change in fair value of contingent consideration		(9,762,845	)		(1,277,551	)
Changes in operating assets and liabilities:
Accounts receivable		21,434,711			(57,040,937	)
Prepaid expenses and other current assets		674,104			(10,507,797	)
Other assets		(297,911	)		362,621
Accounts payable		(6,764,153	)		10,860,517
Accrued liabilities		(10,444,857	)		31,649,586
Net cash provided by (used in) operating activities		12,887,115			(5,918,767	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment		(893,303	)		(3,223,754	)
Acquisition of intangibles		226,130			(62,853	)
Equity method investments		-			(148,422	)
Investment in equity securities		(5,000,000	)		-
Proceeds from disposal of property and equipment		95,892			472,878
Net cash used in investing activities		(5,571,281	)		(2,962,151	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving credit line		-			25,000,000
Repayments of revolving credit line		-			-
Repayments of notes payable		(29,980	)		503,657
Due to seller		(109,619	)		(5,172,446	)
Earnout payments on contingent liabilities		(2,008,524	)		(5,266,681	)
Dividends paid to noncontrolling interest		(1,044,422	)		-
Proceeds from exercise of stock options		25,646			31,885
Payments for taxes related to shares withheld for employee taxes		(794,566	)		(141,972	)
Common stock repurchased		(2,678,073	)		-
Payments on obligations under finance lease		(1,216,409	)		(1,977,223	)
Net cash (used in) provided by financing activities		(7,855,947	)		12,977,220
Effect of exchange rate changes on cash and cash equivalents		(701,078	)		865,746
Net (decrease) increase in cash and restricted cash		(1,241,191	)		4,962,048
Cash and restricted cash at beginning of period		108,578,498			67,255,938
Cash and restricted cash at end of period	$	107,337,307		$	72,217,986

Non-GAAP Financial Measures

The following information provides definitions and reconciliation of non-GAAP financial measures used by the Company to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles (“GAAP”). The Company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measures used by the Company may differ from similarly titled measures used by other companies.

Adjusted Gross Margin

Adjusted gross profit and adjusted gross margin are considered non-GAAP financial measures under SEC rules because they exclude certain amounts included in gross profit and gross margin calculated in accordance with GAAP. Adjusted gross profit is total revenue minus cost of revenue, excluding depreciation and amortization (which are shown separately), and adjusted gross margin is adjusted gross profit as a percentage of total revenue.

The Company’s management believes that adjusted gross margin is useful in evaluating DocGo’s operating performance, as the calculation of this measure excludes the impact of non-cash depreciation and amortization charges. The Company’s management believes that by using adjusted gross margin in conjunction with GAAP gross margin, investors will get a more complete view of what management considers to be the Company’s core operating performance and allow for comparison of this measure when compared to those of prior periods. While many companies use adjusted gross margin as a performance measure, not all companies use identical calculations for determining adjusted gross margin. As such, DocGo’s presentation of adjusted gross margin might not be comparable to similarly titled measures of other companies.

Adjusted EBITDA

Adjusted EBITDA is considered a non-GAAP financial measure under SEC rules because it excludes certain amounts included in net income (loss) calculated in accordance with GAAP. Specifically, adjusted EBITDA is arrived at by taking reported GAAP net income and adding back the following items: net interest expense (income), provision for (benefit from) income taxes, depreciation and amortization, other (income) expense, non-cash equity-based compensation and certain other non-recurring expenses consisting of certain one-time legal settlements and certain one-time expenses incurred in connection with acquisitions and other corporate activities, beyond those that are typically incurred.

The Company’s management believes that its adjusted EBITDA measure is useful in evaluating DocGo’s operating performance, as the calculation of this measure generally eliminates the effect of financing and income taxes and the accounting effects of capital spending and acquisitions, as well as other items of a non-recurring and/or non-cash nature. Adjusted EBITDA is not intended to be a measure of GAAP cash flow, as this measure does not consider certain cash-based expenses, such as payments for taxes or debt service.

Management believes that using adjusted EBITDA in conjunction with GAAP measures such as net income assists investors in getting a more complete picture of the Company’s financial results and operations, affording them with a more complete view of what management considers to be the Company’s core operating performance as well as offering the ability to assess such performance as compared with that of prior periods and management’s public guidance. While many companies use adjusted EBITDA as a performance measure, not all companies use identical calculations for determining adjusted EBITDA. As such, DocGo’s presentation of adjusted EBITDA might not be comparable to similarly titled measures of other companies.

Adjusted EBITDA Margin

Adjusted EBITDA margin is considered a non-GAAP measure under SEC rules. It is calculated by dividing adjusted EBITDA by revenues. Management believes using adjusted EBITDA margin in conjunction with GAAP measures, such as gross margin and/or net margin, is useful to investors because it assists investors in getting a more complete view of what management considers the Company’s core operating performance, as expressed in marginal terms. While many companies use adjusted EBITDA margin as a performance measure, not all companies use identical calculations for determining adjusted EBITDA margin. As such, DocGo’s presentation of adjusted EBITDA margin might not be comparable to similarly titled measures of other companies.

Reconciliation of Non-GAAP Measures

The table below reflects the reconciliation of GAAP gross margin and adjusted gross margin for the three and twelve months ended December 31, 2024 compared to the same periods in 2023:

	Three Months Ended							Twelve Months Ended
	December 31,							December 31,
	2024			2023				2024			2023
Revenue	$	120,833,073		$	199,246,269			$	616,555,132		$	624,288,642
Cost of revenue (exclusive of depreciation and amortization, which are shown separately below)		(80,334,624	)		(132,559,805	)			(402,980,557	)		(428,906,225	)
Depreciation and amortization		(3,322,925	)		(4,615,235	)			(15,884,898	)		(16,431,892	)
GAAP gross profit	$	37,175,524		$	62,071,229			$	197,689,677		$	178,950,525
Depreciation and amortization		3,322,925			4,615,235				15,884,898			16,431,892
Adjusted gross profit	$	40,498,449		$	66,686,464			$	213,574,575		$	195,382,417
GAAP gross margin		30.8	%		31.2	%			32.1	%		28.7	%
Adjusted gross margin		33.5	%		33.5	%			34.6	%		31.3	%

The table below reflects the reconciliation of net income (loss) to adjusted EBITDA for the three and twelve months ended December 31, 2024 compared to the same periods in 2023 (in millions):

	Three Months Ended December 31,							Twelve Months Ended December 31,
	2024			2023				2024			2023
Net income (GAAP)	$	(7.6	)	$	8.0			$	13.4		$	10.0
(+) Net interest expense (income)		0.5			-				1.9			(1.7	)
(+) Income tax		1.1			4.2				14.4			6.2
(+) Depreciation & amortization		3.3			4.6				15.9			16.4
(+) Other (income) expense		(1.4	)		(0.5	)			(1.0	)		0.5
EBITDA	$	(4.1	)	$	16.3			$	44.6		$	31.4
(+) Non-cash stock compensation		3.8			5.8				13.6			21.0
(+) Non-recurring expense		1.4			0.5				2.1			1.6
Adjusted EBITDA	$	1.1		$	22.6			$	60.3		$	54.0
Total revenue	$	121.5		$	199.2			$	616.6		$	624.3
Pretax income margin		-5.3	%		6.1	%			4.5	%		2.6	%
Net margin		-6.3	%		4.0	%			2.2	%		1.6	%
Adjusted EBITDA margin		0.9	%		11.3	%			9.8	%		8.6	%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250227149161/en/

Investors:

Mike Cole

DocGo

949-444-1341

mike.cole@docgo.com

ir@docgo.com

Source: DocGo Inc.

FAQ

What caused DocGo (DCGO) Q4 2024 revenue decline?

DocGo's Q4 revenue declined primarily due to the accelerated wind-down of migrant-related programs with NYC Health and Hospitals and early closure of HPD migrant sites in Upstate NY, impacting revenue by approximately $9.0 million.

How many patient lives are assigned to DocGo's care gap closure programs?

DocGo surpassed 700,000 patient lives assigned for care gap closure programs, up from 2,000 a year ago, with a Net Promoter Score of 86 in Q4 2024.

What is DocGo's (DCGO) revenue guidance for 2025?

DocGo maintains its 2025 revenue guidance at $410-450 million, with an adjusted EBITDA margin expected at approximately 5%.

How much cash does DocGo (DCGO) have as of December 2024?

DocGo held approximately $107.3 million in total cash and cash equivalents, including restricted cash, as of December 31, 2024.

What is the status of DocGo's migrant-related project receivables?

As of year-end 2024, DocGo had approximately $150 million in migrant-related project receivables, expected to be largely collected by the end of Q2 2025.